A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM).

doi:10.1016/j.ejca.2023.113455

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM).

European journal of cancer (Oxford, England : 1990) - 1 Jan 2024

Dayimu Alimu, Gupta Avinash, Matin Rubeta N, Nobes Jenny, Board Ruth, Payne Miranda, Rao Ankit, Fusi Alberto, Danson Sarah, Eccles Bryony, Carser Judith, Brown Ciara O'Hanlon, Steven Neil, Bhattacharyya Madhumita, Brown Ewan, Gonzalez Michael, Highley Martin, Pickering Lisa, Kumar Satish, Waterston Ashita, Burghel George, Demain Leigh, Baker Eleanor, Wulff Jerome, Qian Wendi, Twelves Sophie, Middleton Mark, Corrie Pippa

Abstract excerpt

BACKGROUND: BRAF+MEK inhibitors extend life expectancy of patients with BRAFV600 mutant advanced melanoma. Acquired resistance limits duration of benefit, but preclinical and case studies suggest intermittent dosing could overcome this limitation. INTERIM was a phase 2 trial evaluating an intermittent dosing regimen. METHODS: Patients with BRAFV600 mutant advanced melanoma due to start dabrafenib+trametinib were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Mitogen-Activated Protein Kinase Kinases

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Share to Quality of Life

Share to Skin Neoplasms

Source

Open in PubMed

Identifiers

PMID: 38029480
DOI: 10.1016/j.ejca.2023.113455

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM).PMID 38029480Read ↗

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.Semantic proximity Read ↗

Dosing of BRAK and MEK Inhibitors in Melanoma: No Point in Taking a Break.Semantic proximity Read ↗

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.Semantic proximity Read ↗

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.Semantic proximity Read ↗

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.Semantic proximity Read ↗

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.Semantic proximity Read ↗

Long-Term Response to Intermittent Binimetinib in Patients with NRAS-Mutant Melanoma.Semantic proximity Read ↗

KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.Semantic proximity Read ↗

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.Semantic proximity Read ↗

Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAFV600/NRASQ61 Wild-Type Melanoma (TraMel-WT)Semantic proximity Read ↗

Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic-pharmacodynamic real-life study.Semantic proximity Read ↗

Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.